These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 36819163)

  • 1. Efficacy analysis of different FLT3 inhibitors in patients with relapsed/refractory acute myeloid leukemia and high-risk myelodysplastic syndrome.
    Swaminathan M; Aly MM; Khan AM; Share BA; Dhillon V; Lalo E; Ramos H; Akers KG; Kim S; Balasubramanian S
    EJHaem; 2023 Feb; 4(1):165-173. PubMed ID: 36819163
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Benefits and Safety of FMS-Like Tyrosine Kinase 3 Inhibitors in Various Treatment Stages of Acute Myeloid Leukemia: A Systematic Review, Meta-Analysis, and Network Meta-Analysis.
    Xu Q; He S; Yu L
    Front Oncol; 2021; 11():686013. PubMed ID: 34150652
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML.
    Yilmaz M; Alfayez M; DiNardo CD; Borthakur G; Kadia TM; Konopleva MY; Loghavi S; Kanagal-Shamanna R; Patel KP; Jabbour EJ; Garcia-Manero G; Pemmaraju N; Pierce SA; Ghayas I; Short NJ; Montalban-Bravo G; Takahashi K; Assi R; Alotaibi AS; Ohanian M; Andreeff M; Cortes JE; Kantarjian HM; Ravandi F; Daver NG
    J Hematol Oncol; 2020 Oct; 13(1):132. PubMed ID: 33032648
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Salvage therapy using FLT3 inhibitors may improve long-term outcome of relapsed or refractory AML in patients with FLT3-ITD.
    Takahashi K; Kantarjian H; Pemmaraju N; Andreeff M; Borthakur G; Faderl S; Garcia-Manero G; Pierce S; Luthra R; Cardenas-Turanzas M; Estrov Z; Ravandi F; Cortes J
    Br J Haematol; 2013 Jun; 161(5):659-666. PubMed ID: 23530930
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Outcomes in Patients with FLT3-ITD-Mutated Relapsed/Refractory Acute Myelogenous Leukemia Undergoing Hematopoietic Stem Cell Transplantation after Quizartinib or Salvage Chemotherapy in the QuANTUM-R Trial.
    Ganguly S; Cortes JE; Krämer A; Levis MJ; Martinelli G; Perl AE; Russell NH; Arunachalam M; Santos CD; Gammon G; Lesegretain A; Mires DE; Pham H; Wang Y; Khaled SK
    Transplant Cell Ther; 2021 Feb; 27(2):153-162. PubMed ID: 33017662
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial.
    Cortes J; Perl AE; Döhner H; Kantarjian H; Martinelli G; Kovacsovics T; Rousselot P; Steffen B; Dombret H; Estey E; Strickland S; Altman JK; Baldus CD; Burnett A; Krämer A; Russell N; Shah NP; Smith CC; Wang ES; Ifrah N; Gammon G; Trone D; Lazzaretto D; Levis M
    Lancet Oncol; 2018 Jul; 19(7):889-903. PubMed ID: 29859851
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Efficacy and Safety of Decitabine Combined with Modified EIAG Regimen in the Treatment of Patients with Relapsed/Refractory Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome].
    Mao JP; Xue LG; Zhu YX; Jia T; Wang Y; Miao L; Wei JF; Zhao LD
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Apr; 31(2):338-343. PubMed ID: 37096503
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical and genetic characteristics predict outcomes of acute myeloid leukemia patients with FLT3 mutations receiving venetoclax-based therapy.
    Weng G; Huang J; An N; Zhang Y; Yu G; Sun Z; Lin D; Deng L; Liang X; Xiao J; Zhang H; Guo Z; He X; Jin H; Liu Q; Du X
    Cancer Med; 2024 Jan; 13(2):e6885. PubMed ID: 38334500
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FLT3 inhibitor maintenance after allogeneic stem cell transplantation in
    He G; Belmont E; Karrison T; Stock W; LaBelle JL; Kosuri S; Larson RA; Kline JP; Riedell PA; Nawas M; Bishop MR; Liu H
    Ann Transl Med; 2024 Jun; 12(3):49. PubMed ID: 38911560
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of FLT3 inhibitors in acute myeloid leukemia remission induction or salvage therapy: systematic review and meta-analysis.
    Yang M; Zhao J; Liu T; Yang X; Wei H; Xu W; Xiao J
    Cancer Manag Res; 2018; 10():2635-2652. PubMed ID: 30147364
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Translatome proteomics identifies autophagy as a resistance mechanism to on-target FLT3 inhibitors in acute myeloid leukemia.
    Koschade SE; Klann K; Shaid S; Vick B; Stratmann JA; Thölken M; Meyer LM; Nguyen TD; Campe J; Moser LM; Hock S; Baker F; Meyer CT; Wempe F; Serve H; Ullrich E; Jeremias I; Münch C; Brandts CH
    Leukemia; 2022 Oct; 36(10):2396-2407. PubMed ID: 35999260
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparative study of molecular mutations in 381 patients with myelodysplastic syndrome and in 4130 patients with acute myeloid leukemia.
    Bacher U; Haferlach T; Kern W; Haferlach C; Schnittger S
    Haematologica; 2007 Jun; 92(6):744-52. PubMed ID: 17550846
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical characteristics and outcomes in patients with acute myeloid leukemia with concurrent FLT3-ITD and IDH mutations.
    Shoukier M; Kadia T; Konopleva M; Alotaibi AS; Alfayez M; Loghavi S; Patel KP; Kanagal-Shamanna R; Cortes J; Samra B; Jabbour E; Garcia-Manero G; Takahashi K; Pierce S; Short NJ; Yilmaz M; Sasaki K; Masarova L; Pemmaraju N; Borthakur G; Kantarjian HM; Ravandi F; DiNardo CD; Daver N
    Cancer; 2021 Feb; 127(3):381-390. PubMed ID: 33119202
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patterns of Resistance Differ in Patients with Acute Myeloid Leukemia Treated with Type I versus Type II FLT3 inhibitors.
    Alotaibi AS; Yilmaz M; Kanagal-Shamanna R; Loghavi S; Kadia TM; DiNardo CD; Borthakur G; Konopleva M; Pierce SA; Wang SA; Tang G; Guerra V; Samra B; Pemmaraju N; Jabbour E; Short NJ; Issa GC; Ohanian M; Garcia-Manero G; Bhalla KN; Patel KP; Takahashi K; Andreeff M; Cortes JE; Kantarjian HM; Ravandi F; Daver N
    Blood Cancer Discov; 2021 Mar; 2(2):125-134. PubMed ID: 33681815
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Twice-daily fludarabine and cytarabine combination with or without gentuzumab ozogamicin is effective in patients with relapsed/refractory acute myeloid leukemia, high-risk myelodysplastic syndrome, and blast- phase chronic myeloid leukemia.
    Jabbour E; Garcia-Manero G; Cortes J; Ravandi F; Plunkett W; Gandhi V; Faderl S; O'Brien S; Borthakur G; Kadia T; Burger J; Konopleva M; Brandt M; Huang X; Kantarjian H
    Clin Lymphoma Myeloma Leuk; 2012 Aug; 12(4):244-51. PubMed ID: 22534616
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Classes of ITD Predict Outcomes in AML Patients Treated with FLT3 Inhibitors.
    Schwartz GW; Manning B; Zhou Y; Velu P; Bigdeli A; Astles R; Lehman AW; Morrissette JJD; Perl AE; Li M; Carroll M; Faryabi RB
    Clin Cancer Res; 2019 Jan; 25(2):573-583. PubMed ID: 30181385
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Efficacy and safety of gilteritinib-based combination therapy bridging allo-HSCT in relapsed or refractory acute myeloid leukemia patients with positive FLT3-ITD mutation].
    Xu Y; Zhang J; Xue SL; Miao M; Wang Y; Chen SN; Qiu HY; Wu DP
    Zhonghua Xue Ye Xue Za Zhi; 2024 Apr; 45(4):357-363. PubMed ID: 38951063
    [No Abstract]   [Full Text] [Related]  

  • 18. Evaluation of hypereosinophilia in a case of
    Martinez-Gutierrez LN; Burgher BC; Glynias MJ; Alvarado D; Griffiths EA; Glenn ST; Sung PJ
    Cold Spring Harb Mol Case Stud; 2023 Jun; 9(3):. PubMed ID: 37433680
    [TBL] [Abstract][Full Text] [Related]  

  • 19. French Retrospective Database Analysis of Patient Characteristics and Treatment Patterns in Patients with R/R FLT3-Mutated AML: A Registry-Based Cohort Study.
    Garnham A; Bruon F; Berthon C; Lebon D; Parimi M; Polya R; Makhloufi KM; Dramard-Goasdoue MH
    Oncol Ther; 2023 Sep; 11(3):375-389. PubMed ID: 37578642
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The efficacy and adverse events of venetoclax in combination with hypomethylating agents treatment for patients with acute myeloid leukemia and myelodysplastic syndrome: a systematic review and meta-analysis.
    Liu B; Guo Y; Deng L; Qiao Y; Jian J
    Hematology; 2020 Dec; 25(1):414-423. PubMed ID: 33191860
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.